

**Osoyoos Announces Results of Annual and Special Meeting**

**TORONTO, ONTARIO, August 10, 2020** – Osoyoos Cannabis Inc. (CSE: OSO) (“**Osoyoos**” or the “**Company”**) is pleased to announce the results from the Company’s annual and special meeting of shareholders held on Friday, August 7, 2020 (the “**Meeting**”).

Shareholders holding a total of 34,335,039 common shares of the Company were represented in person or by proxy at the Meeting, representing 46.29% of the votes attached to all outstanding common shares of the Company as at the record date. The Company reports that shareholders voted in favour of all matters submitted before the Meeting with each motion receiving more than 99% support from those votes cast collectively at the Meeting. Such matters approved at the Meeting, as more particularly described and set forth in the Company’s management information circular, dated July 13, 2020, included:

1. The appointment of Buckley Dodds LLP, Chartered Professional Accountants, as auditor of the Company for the ensuing year and authorizing the board of directors to fix its remuneration;
2. A resolution to fix the number of directors to be elected at the Meeting for the ensuing year to be fixed at seven (7);
3. The election of Graham Simmonds, Larry Horwitz, Sara Lee Irwin, Dr. Stephen D. Barnhill, Rosy Mondin, Paul Crath and Dr. Anthony Hall to serve as directors of the Company and to hold office until the next annual meeting of shareholders or until their successors are elected or appointed; and
4. An amendment to the Company’s articles of incorporation to change the name of Osoyoos to Aion Therapeutic Inc. or such other name as the board of directors may determine, in its sole discretion.

The Company would like to remind shareholders that the name change does not take immediate effect and therefore the board of directors will update shareholders with respect to any proposed name change at the appropriate time.

**About Osoyoos Cannabis Inc.**

Osoyoos Cannabis Inc. has a joint-venture agreement with a private, vertically-integrated licensed producer under the *Cannabis Act (Canada)* to offer contract tolling extraction services to third-party businesses. Additionally, the Company recently acquired 1196691 B.C. Ltd. d/b/a “PCAI Pharma” ([www.pcai.ca](http://www.pcai.ca)) and its wholly-owned subsidiary AI Pharmaceuticals Jamaica Limited, a private corporation incorporated and operating under the laws of Jamaica. The business of AI Pharma involves science, research, treatment, data mining and AI, focused on the development of combinatorial pharmaceuticals, nutraceuticals and cosmeceuticals utilizing compounds from cannabis (cannabinoids), psychedelic mushrooms (psilocybin), fungi and other psychedelic formulations and their related medicinal global intellectual property protection.

**For further information, please contact:**

**Graham Simmonds**

Chief Executive Officer

(416) 843-2881

jgrahamsimmonds@gmail.com

**DISCLAIMER & READER ADVISORY**

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “may”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the parties. The material factors and assumptions include regulatory and other third-party approvals; licensing and other risks. The forward-looking information contained in this release is made as of the date hereof and the parties are not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.